Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG study.

Autor: Beypınar İ; Department of Medical Oncology, Alanaya Alaaddin Keykubat University, Alanya, Turkey. ibeypinar@yahoo.com., Demir H; Department of Medical Oncology, Afyonkarahisar Health Sciences University, Afyon, Turkey., Yaslıkaya Ş; Department of Medical Oncology, Çukurova University, Adana, Turkey., Köşeci T; Department of Medical Oncology, Çukurova University, Adana, Turkey., Demir B; Department of Medical Oncology, Aydın Adnan Menderes University, Aydın, Turkey., Çolak G; Department of Medical Oncology, Aydın Adnan Menderes University, Aydın, Turkey., Ağaoğlu AB; Department of Medical Oncology, Celal Bayar University, Manisa, Turkey., Şahbazlar M; Department of Medical Oncology, Celal Bayar University, Manisa, Turkey., Şancı PC; Department of Medical Oncology, Kocaeli University, Kocaeli, Turkey., Çabuk D; Department of Medical Oncology, Kocaeli University, Kocaeli, Turkey., Işık U; Department of Medical Oncology, Kocaeli City Hospital, Kocaeli, Turkey., Şahin E; Department of Medical Oncology, Kocaeli City Hospital, Kocaeli, Turkey., Coşkun A; Department of Medical Oncology, Uludağ University, Bursa, Turkey., Caner B; Department of Medical Oncology, Uludağ University, Bursa, Turkey., Aykut T; Department of Medical Oncology, Necmettin Erbakan University, Konya, Turkey., Artaç M; Department of Medical Oncology, Necmettin Erbakan University, Konya, Turkey., Duygulu ME; Department of Medical Oncology, Karadeniz Technical University, Trabzon, Turkey., Sever N; Department of Medical Oncology, Marmara University, Istanbul, Turkey., Öksüz S; Department of Medical Oncology, Kartal Lütfü Kırdar Research and Education Hospital, Istanbul, Turkey., Turan N; Department of Medical Oncology, Kartal Lütfü Kırdar Research and Education Hospital, Istanbul, Turkey., Aykan MB; Department of Medical Oncology, Gülhane Research and Education Hospital, Ankara, Turkey., Tüzün EK; Department of Medical Oncology, Gülhane Research and Education Hospital, Ankara, Turkey., Uysal M; Department of Medical Oncology, Vocational School of Health Services, Medstar Antalya Hospital, Antalya Bilim University, Antalya, Turkey., Uğurlu İ; Department of Medical Oncology, Sakarya Research and Education Hospital, Sakarya, Turkey., Sakin A; Department of Medical Oncology, Medipol University, Istanbul, Turkey., Acar C; Department of Medical Oncology, Ege University, İzmir, Turkey., Özaşkın D; Department of Medical Oncology, Afyonkarahisar Health Sciences University, Afyon, Turkey., Şakalar T; Department of Medical Oncology, Kahramanmaraş Necip Fazıl City Hospital, Kahramanmaraş, Turkey., Keskinkılıç M; Department of Medical Oncology, Dokuz Eylül University, İzmir, Turkey., Yavuzşen T; Department of Medical Oncology, Dokuz Eylül University, İzmir, Turkey., Köse N; Department of Medical Oncology, Memorial Hospital, Ankara, Turkey., Ertürk İ; Department of Medical Oncology, Gülhane Research and Education Hospital, Ankara, Turkey., Yıldırım N; Department of Medical Oncology, Fırat University, Elazığ, Turkey., Balçık OY; Department of Medical Oncology, Alanaya Alaaddin Keykubat University, Alanya, Turkey., Alkan A; Department of Medical Oncology, Muğla Sıtkı Koçman University, Muğla, Turkey., Selvi O; Department of Medical Oncology, Prof.Dr Cemil Taşçıoğlu City Hospital, Istanbul, Turkey., Erçin E; Department of Medical Oncology, Ümraniye Research and Education Hospital, Istanbul, Turkey., Ünal OÜ; Department of Medical Oncology, Tepecik Research and Education Hospital, İzmir, Turkey., Karaçin C; Department of Medical Oncology, Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey.
Jazyk: angličtina
Zdroj: Breast cancer research and treatment [Breast Cancer Res Treat] 2024 Dec; Vol. 208 (3), pp. 597-604. Date of Electronic Publication: 2024 Aug 09.
DOI: 10.1007/s10549-024-07456-x
Abstrakt: Purpose: In advanced breast cancer, endocrine therapy is preferred in the absence of visceral crisis. Cyclin-dependent kinase inhibitors (CDKi) are the gold standards. The selection of subsequent treatments after CDKi treatment is still controversial, and the efficacy of everolimus (EVE) combinations is unknown. In this study, we aimed to investigate the efficacy of EVE after CDKi administration in real-life experiences.
Method: The study received data from 208 patients from 26 cancer centers. Demographic and histologic features, diagnosis, progression, last visit dates, and toxicities were recorded. This study was a retrospective case series.
Results: One hundred and seven patients received palbociclib, while 101 patients received ribociclib as a CDKi. The overall response and disease control rates of EVE combinations were 60% and 88%, respectively. In univariate analysis, the absence of liver metastasis, age > 40 years, better type of response, and immediate treatment after CDKi were related to increased progression-free survival. Liver metastasis and response type were significantly associated with overall survival. In the multivariate analysis, response remained significant in terms of progression-free survival, while response type, liver metastatic disease, and hematologic toxicity were prognostic in terms of overall survival.
Conclusion: This study provides evidence of the benefits of EVE combinations after CDKi treatment. EVE combinations may be more appropriate for patients with non-liver metastasis, and the first treatment response shows the benefit of treatment. In addition, immediate treatment after CDKi treatment is more beneficial than later lines of treatment.
(© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: